Field Medical's PFA Catheter Hits 94.2% Vein Durability in 12-Month Trial
Atlanta and Carlsbad, Calif. – September 20, 2026 -- Field Medical, Inc. reported 12-month outcomes from its first-in-human Field PULSE trial showing 94.2% per-vein durability for pulmonary vein isolation using an optimized waveform, with results published in JACC: Clinical Electrophysiology and presented as a Late-Breaking Clinical Trial at HRX Live 2026.
Subsecond ablation cuts median procedure time to 13 minutes
The trial recorded a 13-minute median elapsed pulmonary vein isolation (PVI) ablation time, with a fastest case completed in 7.7 minutes. Field Medical's high-voltage focal pulsed field ablation (PFA) architecture, delivered through its FieldForce PFA System, applies energy in under 200 milliseconds per point, reducing the need for prolonged catheter stability during atrial procedures.